SGLT-2抑制剂达格列净治疗2型糖尿病肾病患者的价值研究  

The Value of SGLT-2 Inhibitor Dapagliflozin in the Treatment of Type 2 Diabetic Nephropathy

作　　者：刘涛 LIU Tao(Department of Endocrinology,Jiaocheng Hospital,Ningde,Fujian Province,352100 China)

机构地区：[1]福建省宁德市蕉城区医院内分泌科,福建宁德352100

出　　处：《糖尿病新世界》2021年第3期13-15,共3页Diabetes New World Magazine

摘　　要：目的研究对2型糖尿病肾病患者开展SGLT-2抑制剂达格列净治疗的临床价值。方法遵从"平衡序贯法"分组,将该院2019年3月—2020年6月收治的70例2型糖尿病肾病患者分为对照组(33例,血管转化酶抑制剂ACEI依那普利常规治疗)和观察组(37例,SGLT-2抑制剂达格列净治疗),观察临床疗效、血糖水平、肾脏功能以及血清炎症因子情况。结果观察组显效26例,有效10例,临床疗效高达97.2%,明显比78.7%的对照组高,差异有统计学意义(χ^(2)=5.904,P<0.05)。治疗后观察组血糖以及血清炎症因子水平较低,肾脏功能较好,与对照组比较差异有统计学意义(P<0.05)。结论对2型糖尿病肾病患者开展药物治疗,建议采纳SGLT-2抑制剂达格列净,可有效提高治疗效果并改善患者预后。Objective To study the clinical value of SGLT-2 inhibitor dapagliflozin treatment in patients with type 2 diabetic nephropathy.Methods According to the"balance sequential method"grouping,70 cases in the hospital admitted from March 2019 to June 2020 were divided into control group(33 cases,conventional treatment with vascular converting enzyme inhibitor ACEI enalapril)and observation group(37 cases,SGLT-2 inhibitor dapagliflozin treatment),observed the clinical efficacy,blood glucose level,kidney function and serum inflammatory factors.Results There were 26 cases in the observation group,10 cases in effect,and the clinical effect was as high as 97.2%,which was significantly higher than that in the control group(78.7%),the difference was statistically significant(χ^(2)=5.904,P<0.05).After treatment,the observation group had lower blood glucose and serum inflammatory factor levels,and better kidney function.Compared with the control group the difference was statistically significant(P<0.05).Conclusion For patients with type 2 diabetic nephropathy,it is recommended to adopt SGLT-2 inhibitor dapagliflozin,which can effectively improve the treatment effect and improve the prognosis of patients.

关 键 词：SGLT-2抑制剂 达格列净 血管转化酶抑制剂 依那普利 2型糖尿病肾病 

分 类 号：R58[医药卫生—内分泌]